Physician profile
Jansen Wuisan
NPI 1205477247
$2,651.14
in general payments reported to CMS, 2019-2025
15 companies · $477 in 2025
The $477 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $425 · 2022: $811 · 2023: $817 · 2024: $122 · 2025: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,407 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,407.41 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $465.21 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $438.51 | 2021-2023 | Fasenra |
| Novo Nordisk INC | $351.91 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $128.56 | 2023 | |
| Neurocrine Biosciences, INC. | $127.25 | 2022 | |
| Esperion Therapeutics, INC. | $125.00 | 2022 | |
| Axsome Therapeutics, INC. | $124.78 | 2025 | Auvelity |
| Regeneron Healthcare Solutions, INC. | $121.84 | 2024 | Evkeeza |
| Bayer Healthcare Pharmaceuticals INC. | $117.64 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $116.28 | 2022 | |
| Merck Sharp & Dohme LLC | $114.05 | 2023 | Verquvo |
| Sanofi-Aventis U.S. LLC | $112.79 | 2025 | |
| Urovant Sciences INC | $109.51 | 2021 | |
| Corcept Therapeutics | $99.04 | 2023 | Korlym |
| Alkermes, INC. | $98.77 | 2023 | Lybalvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jansen Wuisan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.